A Phase Ib/II Clinical Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 05 Apr 2018
At a glance
- Drugs Amcasertib (Primary) ; Capecitabine; Doxorubicin; Nivolumab; Paclitaxel; Pembrolizumab; Sunitinib
- Indications Cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Boston Biomedical
- 30 Mar 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Dec 2018.
- 30 Mar 2018 Status changed from recruiting to active, no longer recruiting.
- 13 Oct 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Mar 2018.